

Alexis B Cortot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7227924/publications.pdf>

Version: 2024-02-01

86
papers

6,508
citations

172386

29
h-index

66879

78
g-index

95
all docs

95
docs citations

95
times ranked

7385
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2017, 389, 917-929.	6.3	919
2	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature</i> , 2009, 462, 1070-1074.	13.7	886
3	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. <i>Annals of Oncology</i> , 2019, 30, 1321-1328.	0.6	842
4	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	0.8	572
5	Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	13.9	500
6	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	5.1	418
7	Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. <i>Cancer Research</i> , 2013, 73, 834-843.	0.4	171
8	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 771-781.	5.2	167
9	Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i> -positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. <i>Oncotarget</i> , 2017, 8, 21903-21917.	0.8	140
10	Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. <i>European Respiratory Review</i> , 2014, 23, 356-366.	3.0	139
11	Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS@ phase II trial. <i>Annals of Oncology</i> , 2019, 30, 1985-1991.	0.6	128
12	Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History. <i>Cancer Research</i> , 2007, 67, 5667-5672.	0.4	111
13	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy. <i>International Journal of Cancer</i> , 2009, 125, 2479-2482.	2.3	103
14	Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	83
15	Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. <i>European Radiology</i> , 2013, 23, 2127-2136.	2.3	71
16	<i>KRAS</i> mutation status in primary nonsmall cell lung cancer and matched metastases. <i>Cancer</i> , 2010, 116, 2682-2687.	2.0	67
17	Defining the "Frequent Exacerbator" Phenotype in COPD. <i>Chest</i> , 2018, 153, 1106-1115.	0.4	64
18	Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2022, 28, 1117-1126.	3.2	52

#	ARTICLE	IF	CITATIONS
19	Phase II study of tepotinib in NSCLC patients with <i>MET</i> exon 14 mutations.. Journal of Clinical Oncology, 2019, 37, 9005-9005.	0.8	49
20	c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Journal of Thoracic Oncology, 2018, 13, 1962-1967.	0.5	48
21	Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations. Journal of Thoracic Oncology, 2020, 15, 741-751.	0.5	48
22	The multiple paths towards MET receptor addiction in cancer. Oncogene, 2018, 37, 3200-3215.	2.6	44
23	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. European Journal of Cancer, 2020, 131, 27-36.	1.3	44
24	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. Journal of Clinical Oncology, 2018, 36, 9010-9010.	0.8	40
25	Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Medicine, 2018, 7, 5505-5513.	1.3	39
26	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial. Journal of Clinical Oncology, 2022, 40, 719-728.	0.8	37
27	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. Frontiers in Oncology, 2020, 10, 578756.	1.3	36
28	Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer. European Respiratory Journal, 2013, 42, 1357-1364.	3.1	31
29	Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer, 2019, 127, 96-102.	0.9	31
30	Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients. Journal of Thoracic Oncology, 2018, 13, 1873-1883.	0.5	30
31	Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2017, 8, 105103-105114.	0.8	27
32	Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study. BMC Cancer, 2018, 18, 178.	1.1	25
33	MET amplification increases the metastatic spread of EGFR-mutated NSCLC. Lung Cancer, 2018, 125, 57-67.	0.9	25
34	PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells. Molecular Oncology, 2015, 9, 1852-1867.	2.1	24
35	High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. Journal of Thoracic Oncology, 2020, 15, 120-124.	0.5	24
36	Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study. Lung Cancer, 2013, 80, 197-202.	0.9	22

#	ARTICLE	IF	CITATIONS
37	In which context is physician empathy associated with cancer patient quality of life?. Patient Education and Counseling, 2018, 101, 1216-1222.	1.0	22
38	Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review. Clinical Lung Cancer, 2022, 23, 195-207.	1.1	22
39	Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas. Clinical Lung Cancer, 2014, 15, 124-130.	1.1	19
40	Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clinical Lung Cancer, 2020, 21, e10-e14.	1.1	18
41	Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence. Current Oncology Reports, 2018, 20, 18.	1.8	17
42	Profiles of caregivers most at risk of having unmet supportive care needs: Recommendations for healthcare professionals in oncology. European Journal of Oncology Nursing, 2019, 43, 101669.	0.9	17
43	Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.. Journal of Clinical Oncology, 2016, 34, 9005-9005.	0.8	17
44	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer, 2019, 136, 109-114.	0.9	16
45	Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. ESMO Open, 2018, 3, e000414.	2.0	15
46	Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy. Nuclear Medicine Communications, 2014, 35, 908-915.	0.5	14
47	Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. Clinical Lung Cancer, 2019, 20, 297-304.e1.	1.1	14
48	Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. European Journal of Cancer, 2022, 166, 51-59.	1.3	14
49	Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer. European Radiology, 2017, 27, 3733-3743.	2.3	13
50	Current and Former Smokers: Who Wants To Be Screened?. Clinical Lung Cancer, 2018, 19, 493-501.	1.1	13
51	Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial. Clinical Cancer Research, 2020, 26, 3172-3181.	3.2	13
52	When the MET receptor kicks in to resist targeted therapies. Oncogene, 2021, 40, 4061-4078.	2.6	13
53	Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy. Journal of Thoracic Imaging, 2015, 30, 300-307.	0.8	12
54	Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. Lung Cancer, 2020, 142, 63-69.	0.9	12

#	ARTICLE	IF	CITATIONS
55	Physician Empathy Interacts with Breaking Bad News in Predicting Lung Cancer and Pleural Mesothelioma Patient Survival: Timing May Be Crucial. <i>Journal of Clinical Medicine</i> , 2018, 7, 364.	1.0	11
56	Dual-Energy CT Perfusion of Invasive Tumor Front in Non-“Small Cell Lung Cancers. <i>Radiology</i> , 2022, 302, 448-456.	3.6	11
57	Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party. <i>Frontiers in Oncology</i> , 2015, 4, 386.	1.3	9
58	<i>ALK</i>-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 225-233.	1.1	9
59	First-Line Afatinib plus Cetuximab for <i>EGFR</i>-Mutant Non-“Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. <i>Clinical Cancer Research</i> , 2021, 27, 4168-4176.	3.2	9
60	High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form. <i>Lung Cancer</i> , 2016, 101, 59-67.	0.9	8
61	Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i>+ advanced non-small cell lung cancer patients. <i>ERJ Open Research</i> , 2018, 4, 00058-2017.	1.1	8
62	Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. <i>Cancers</i> , 2022, 14, 1498.	1.7	8
63	Paclitaxel+bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210993.	1.4	8
64	Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-“Small Cell Lung Carcinomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 414-422.	2.1	7
65	MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering. <i>Oncotarget</i> , 2017, 8, 11268-11283.	0.8	7
66	A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-“Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation. <i>Clinical Lung Cancer</i> , 2022, 23, e131-e134.	1.1	7
67	IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9003-9003.	0.8	6
68	Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer”Letter. <i>Clinical Cancer Research</i> , 2016, 22, 1827-1827.	3.2	5
69	Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. <i>Clinical Lung Cancer</i> , 2022, 23, 320-332.	1.1	5
70	Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?. <i>Annals of Translational Medicine</i> , 2016, 4, 96-96.	0.7	4
71	Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. <i>Preventive Medicine Reports</i> , 2018, 10, 332-336.	0.8	4
72	Comprehensive Genome Profiling in Patients With Metastatic Non-“Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIRO2-Lung/IFCT 1301 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4018-4026.	3.2	4

#	ARTICLE	IF	CITATIONS
73	OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S284-S285.	0.5	3
74	Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study. <i>Annals of Oncology</i> , 2019, 30, vi108-vi109.	0.6	2
75	Can Studies on Early Palliative Care Be Harmful to Patient Well Being?. <i>Journal of Palliative Medicine</i> , 2019, 22, 1488-1488.	0.6	2
76	Cancer screening in France: Reaching a plateau? New edition of an iterative nationwide survey.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1565-1565.	0.8	2
77	Dose-seeking phase I trials (DSP1T) for currently approved molecular-targeted therapies (MTT): We are still far from using appropriate designs.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3034-3034.	0.8	1
78	Awareness and misconceptions of colorectal cancer risk factors among laypersons and physicians.. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-536.	0.8	1
79	Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue. <i>Pharmaceutical Medicine</i> , 2016, 30, 143-147.	1.0	0
80	Factors influencing colorectal cancer screening participation rates in 2016. <i>Annals of Oncology</i> , 2017, 28, iii90-iii91.	0.6	0
81	Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. , 2011, , 1-31.		0
82	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11076-11076.	0.8	0
83	Metamplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer. , 2015, , .		0
84	First things first: Prevention, screening or care?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1550-1550.	0.8	0
85	Clinical outcomes of patients with lung cancer treated with radiotherapy and ANTI-PD-1 therapy: A multicenter retrospective analysis from GFPC Group.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21077-e21077.	0.8	0
86	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. <i>Lung Cancer</i> , 2021, 164, 84-90.	0.9	0